# EDGAR Filing Document

**Accession Number:** 0001913577
**File Stem:** 0001193125-25-177416
**Filing Date:** 2025-8
**Character Count:** 47026
**Document Hash:** 9d908d0015286a38bf2c24024e947867
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-177416.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001193125-25-177416

**CONFORMED SUBMISSION TYPE**: S-4/A

**PUBLIC DOCUMENT COUNT**: 13

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Denali Capital Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001913577
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-4/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-283019
- **FILM NUMBER:** 251200043

**BUSINESS ADDRESS:**
- **STREET 1:** 437 MADISON AVENUE
- **STREET 2:** 27TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 6469785180

**MAIL ADDRESS:**
- **STREET 1:** 437 MADISON AVENUE
- **STREET 2:** 27TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Semnur Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001584541
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462968523
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-4/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-283019-01
- **FILM NUMBER:** 251200044

**BUSINESS ADDRESS:**
- **STREET 1:** 849 AVERY DRIVE
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94043
- **BUSINESS PHONE:** (847) 612-9284

**MAIL ADDRESS:**
- **STREET 1:** 849 AVERY DRIVE
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94043

**As filed with the U.S. Securities and Exchange Commission on August 11, 2025** 

**Registration No. 333-283019** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Amendment No. 6** 

**to** 

**Form S-4** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Denali Capital Acquisition Corp.
**(Exact name of registrant as specified in its charter)** 

**For Co-Registrants, see "Table of Co-Registrants" on the following page.** 

---

| | | |
|:---|:---|:---|
| **Cayman Islands\*** | **6770** | **92-2371901** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Primary Standard Industrial**<br> **Classification Code Number)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**437 Madison Avenue, 27th Floor** 

**New York, NY 10022** 

**(646) 978-5180** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Lei Huang** 

**Chief Executive Officer** 

**437 Madison Avenue, 27th Floor** 

**New York, NY 10022** 

**(646) 978-5180** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Michael J. Blankenship, Esq.**<br> **Winston & Strawn LLP**<br> **800 Capital Street, Suite 2400**<br> **Houston, TX 77002** | **Jeffrey T. Hartlin, Esq.**<br> **Elizabeth A. Razzano, Esq.**<br> **Paul Hastings LLP**<br> **1117 S. California Avenue**<br> **Palo Alto, CA 94304** |

---

**Approximate date of commencement of proposed sale to the public**: As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.

If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Registrant and Co-Registrant:

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:

Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) ☐ <br> Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) ☐

\* Immediately prior to the consummation of the Business Combination described in the proxy statement/prospectus, Denali Capital Acquisition Corp. intends to effect a deregistration under the Cayman Islands Companies Act (2023 Revision) (As Revised) ("Companies Act") and a domestication under Section 388 of the Delaware General Corporation Law, pursuant to which the jurisdiction of incorporation for Denali Capital Acquisition Corp. will be changed from the Cayman Islands to the State of Delaware (the "Domestication"). All securities being registered will be issued by the continuing entity following the Domestication, which will be renamed "Semnur Pharmaceuticals, Inc." in connection with the Business Combination, as further described in the proxy statement/prospectus. Except where otherwise noted, as used herein, the "Company" refers to Denali Capital Acquisition Corp. as a Delaware corporation by way of continuation following the Domestication and the Business Combination, which in connection with the Domestication and simultaneously with the Business Combination, will change its corporate name to "Semnur Pharmaceuticals, Inc." 

**The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.**

------

**TABLE OF CO-REGISTRANTS** 

---

| | | | |
|:---|:---|:---|:---|
| **Exact Name of Co-Registrant as Specified in its Charter<sup>(1)(2)</sup>** | **State or Other<br>Jurisdiction of<br>Incorporation or<br>Organization** | **Primary<br>Standard<br>Industrial<br>Classification<br>Code Number** | **I.R.S. Employer<br>Identification Number** |
|  Semnur Pharmaceuticals, Inc. | Delaware | 2836 | 46-2968523 |

---

(1) The Co-Registrant has the following principal executive office:

Semnur Pharmaceuticals, Inc.

960 San Antonio Road

Palo Alto, CA 94303

(2) The agent for service for the Co-Registrant is:

Jaisim Shah

Chief Executive Officer and President

Semnur Pharmaceuticals, Inc.

960 San Antonio Road

Palo Alto, CA 94303

(650) 516-4310

------

**EXPLANATORY NOTE** 

This Amendment No.6 ("Amendment No. 6") to the Registration Statement on Form S-4 (File No. 333-283019) of Denali Capital Acquisition Corp. (the "Registration Statement") is being filed as an exhibits-only filing to amend Exhibit 107 in Part II of this Amendment No. 6. This Amendment No. 6 does not modify any provision of the proxy statement/prospectus that forms a part of the Registration Statement. Accordingly, this Amendment No. 6 consists only of the cover page, this explanatory note, Item 21 of Part II of the Registration Statement, the signature pages to the Registration Statement, and the filed exhibit.

------

**PART II** 

**INFORMATION NOT REQUIRED IN THE PROSPECTUS** 

**Item 21. Exhibits and Financial Statements Schedules** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 1.1 | [Underwriting Agreement, dated as of April 6, 2022, by and among Denali Capital Acquisition Corp., US Tiger Securities, Inc. and EF Hutton, division of Benchmark Investments, LLC, as representatives of the several underwriters named therein. (incorporated by reference to Exhibit 1.1 of Denali's Current Report on Form 8-K filed with the SEC on April 12, 2022).](http://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/sa016_ex1-1.htm) |
| 2.1#‡ | [Agreement and Plan of Merger, dated as of March 18, 2019, by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the representative of the Equityholders and, solely with respect to Section 1.8(a), Section 3.11 and Article X, Sorrento Therapeutics, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex21.htm) |
| 2.2‡ | [Amendment No. 1 to Agreement and Plan of Merger, dated as of August 7, 2019, by and among Semnur Pharmaceuticals, Inc., Scilex Holding Company, Sigma Merger Sub, Inc., Fortis Advisors, LLC, solely as the representative of the Equityholders and, solely with respect to Section 1.8(a), 3.11 and Article X of the Agreement and Plan of Merger, Sorrento Therapeutics, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex22.htm) |
| 2.3#‡ | [Agreement and Plan of Merger, dated as of August 30, 2024, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc. (included as Annex A-1 to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_269) |
| 2.4‡ | [Amendment No. 1 to Agreement and Plan of Merger, dated as of April 16, 2025, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc. (included as Annex A-2 to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_269a) |
| 2.5‡ | [Amendment No. 2 to Agreement and Plan of Merger, dated as of July 22, 2025, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc. (included as Annex A-3 to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_270ab) |
| 3.1 | [Amended and Restated Memorandum and Articles of Association of Denali Capital Acquisition Corp. (incorporated by reference to Exhibit 3.1 of Denali's Current Report on Form 8-K filed with the SEC on April 12, 2022).](http://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/sa016_ex3-1.htm) |
| 3.2 | [Extension Amendment, dated as of October 11, 2023, to the Amended and Restated Memorandum and Articles of Association of Denali Capital Acquisition Corp. (incorporated by reference to Exhibit 3.1 of Denali's Current Report on Form 8-K filed with the SEC on October 11, 2023).](http://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/ea186607ex3-1_denalicap.htm) |
| 3.3 | [Extension Amendment, dated as of July 10, 2024, to the Amended and Restated Memorandum and Articles of Association of Denali Capital Acquisition Corp. (incorporated by reference to Exhibit 3.1 of Denali's Current Report on Form 8-K filed with the SEC on July 10, 2024).](http://www.sec.gov/Archives/edgar/data/1913577/000121390024060537/ea020917601ex3-1_denali.htm) |
| 3.4 | [Extension Amendment, dated as of April 11, 2025, to the Amended and Restated Memorandum and Articles of Association of Denali Capital Acquisition Corp. (incorporated by reference to Exhibit 3.1 of Denali's Current Report on Form 8-K filed with the SEC on April 15, 2025).](http://www.sec.gov/Archives/edgar/data/1913577/000121390025032299/ea023848801ex3-1_denali.htm) |
| 3.5‡ | [Form of Certificate of Domestication of Denali Capital Acquisition Corp., to be filed with the Secretary of State of Delaware.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex35.htm) |
| 3.6‡ | [Form of Certificate of Incorporation of Denali Capital Acquisition Corp. (included as Annex B to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_270) |
| 3.7‡ | [Form of Certificate of Designations of Semnur Pharmaceuticals, Inc. (included as Annex G to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_275) |

---

------

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 3.8‡ | [Form of Bylaws of Denali Capital Acquisition Corp. (included as Annex C to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_271) |
| 4.1 | [Specimen Unit Certificate of Denali Capital Acquisition Corp. (incorporated by reference to Exhibit 4.1 of Denali's Form S-1 filed with the SEC on April 5, 2022).](http://www.sec.gov/Archives/edgar/data/1913577/000157587222000204/sa002_ex4-1.htm) |
| 4.2 | [Specimen Class A Ordinary Share Certificate of Denali Capital Acquisition Corp. (incorporated by reference to Exhibit 4.2 of Denali's Form S-1 filed with the SEC on April 5, 2022).](http://www.sec.gov/Archives/edgar/data/1913577/000157587222000204/sa002_ex4-2.htm) |
| 4.3 | [Specimen Warrant Certificate of Denali Capital Acquisition Corp. (incorporated by reference to Exhibit 4.3 of Denali's Form S-1 filed with the SEC on April 5, 2022).](http://www.sec.gov/Archives/edgar/data/1913577/000157587222000204/sa002_ex4-3.htm) |
| 4.4 | [Warrant Agreement, dated as of April 6, 2022, between Denali Capital Acquisition Corp. and VStock Transfer, LLC, as warrant agent (incorporated by reference to Exhibit 4.1 of Denali's Current Report on Form 8-K filed with the SEC on April 12, 2022).](http://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/sa016_ex4-1.htm) |
| 5.1‡ | [Opinion of Winston & Strawn LLP regarding the validity of the securities.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525177097/d887184dex51.htm) |
| 8.1‡ | [Opinion of Winston & Strawn LLP regarding tax matters.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525177097/d887184dex81.htm) |
| 10.1 | [Letter Agreement, dated as of April 6, 2022, by and among Denali Capital Acquisition Corp., Denali Capital Global Investments LLC and certain security holders named therein (incorporated by reference to Exhibit 10.5 of Denali's Current Report on Form 8-K filed with the SEC on April 12, 2022).](http://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/sa016_ex10-5.htm) |
| 10.2 | [Investment Management Trust Agreement, dated as of April 6, 2022, by and between Denali Capital Acquisition Corp. and Wilmington Trust, National Association, as trustee (incorporated by reference to Exhibit 10.1 of Denali's Current Report on Form 8-K filed with the SEC on April 12, 2022).](http://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/sa016_ex10-1.htm) |
| 10.3 | [Registration and Shareholder Rights Agreement, dated as of April 6, 2022, by and among Denali Capital Acquisition Corp., Denali Capital Global Investments LLC and certain security holders named therein (incorporated by reference to Exhibit 10.2 of Denali's Current Report on Form 8-K filed with the SEC on April 12, 2022).](http://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/sa016_ex10-2.htm) |
| 10.4‡ | [Second Amended and Restated Convertible Promissory Note, dated as of April 2, 2024, issued by Denali Capital Acquisition Corp. to Denali Capital Global Investments LLC.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex104.htm) |
| 10.5 | [Convertible Promissory Note, dated as of July 11, 2023, issued by Denali Capital Acquisition Corp. to FutureTech Capital LLC (incorporated by reference to Exhibit 10.1 to Denali's Current Report on Form 8-K filed with the SEC on July 13, 2023).](http://www.sec.gov/Archives/edgar/data/1913577/000121390023056618/ea181625ex10-1_denalicap.htm) |
| 10.6 | [Convertible Promissory Note, dated as of October 11, 2023, issued by Denali Capital Acquisition Corp. to FutureTech Capital LLC (incorporated by reference to Exhibit 10.1 to Denali's Current Report on Form 8-K filed with the SEC on October 11, 2023).](http://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/ea186607ex10-1_denalicap.htm) |
| 10.7 | [Deferred Discount Agreement, dated as of November 20, 2023, by and among Denali Capital Acquisition Corp., Denali SPAC Holdco, Inc., US Tiger Securities, Inc., EF Hutton, division of Benchmark Investments, LLC and Craig-Hallum Capital Group LLC (incorporated by reference to Exhibit 10.2 to Denali's Current Report on Form 8-K filed with the SEC on November 20, 2023).](http://www.sec.gov/Archives/edgar/data/1913577/000121390023088773/ea188711ex10-2_denalicap.htm) |
| 10.8 | [Convertible Promissory Note, dated as of July 10, 2024, by and between Denali Capital Acquisition Corp. and Denali Capital Global Investments LLC (incorporated by reference to Exhibit 10.1 to Denali's Current Report on Form 8-K filed with the SEC on July 10, 2024).](http://www.sec.gov/Archives/edgar/data/1913577/000121390024060537/ea020917601ex10-1_denali.htm) |
| 10.9 | [Convertible Promissory Note, dated as of August 9, 2024, by and between Denali Capital Acquisition Corp. and Scilex Holding Company (incorporated by reference to Exhibit 10.1 to Denali's Current Report on Form 8-K filed with the SEC on August 9, 2024).](http://www.sec.gov/Archives/edgar/data/1913577/000121390024067209/ea021100601ex10-1_denali.htm) |

---

------

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 10.10‡ | [Form of Amended and Restated Registration Rights Agreement, by and among Semnur Pharmaceuticals, Inc., Scilex Holding Company and certain security holders (included as Annex F to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_274) |
| 10.11\*‡ | [Form of Indemnification Agreement of Semnur Pharmaceuticals, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1011.htm) |
| 10.12\*‡ | [2024 Semnur Pharmaceuticals, Inc. Stock Option Plan.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1012.htm) |
| 10.13\*‡ | [Form of Stock Option Grant Notice and Form of Stock Option Agreement under 2024 Semnur Pharmaceuticals, Inc. Stock Option Plan.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1013.htm) |
| 10.14^‡ | [Sponsor Support Agreement, dated as of August 30, 2024, by and among Denali Capital Acquisition Corp., Semnur Pharmaceuticals, Inc. and each of the Persons set forth on Schedule I attached thereto (included as Annex D to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_272) |
| 10.15#‡ | [Company Stockholder Support Agreement, dated as of August 30, 2024, by and among Scilex Holding Company, Semnur Pharmaceuticals, Inc. and Denali Capital Acquisition Corp (included as Annex E to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_273) |
| 10.16# | [Sponsor Interest Purchase Agreement, dated as of August 30, 2024, by and between Denali Capital Global Investments LLC and Scilex Holding Company (incorporated by reference to Exhibit 10.3 to Denali's Current Report on Form 8-K filed with the SEC on September 5, 2024).](http://www.sec.gov/Archives/edgar/data/1913577/000121390024075736/ea021318602ex10-3_denali.htm) |
| 10.17#‡ | [Contribution and Satisfaction of Indebtedness Agreement, dated as of August 30, 2024, by and between Scilex Holding Company and Semnur Pharmaceuticals, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1017.htm) |
| 10.18 | [Stockholder Agreement, dated as of August 30, 2024, by and between Denali Capital Acquisition Corp. and Scilex Holding Company (incorporated by reference to Exhibit 10.4 to Denali's Current Report on Form 8-K filed with the SEC on September 5, 2024).](http://www.sec.gov/Archives/edgar/data/1913577/000121390024075736/ea021318602ex10-4_denali.htm) |
| 10.19^‡ | [Master Services Agreement—SP-102, dated as of January 27, 2017, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1019.htm) |
| 10.20‡ | [Amendment No. 1 to Master Services Agreement, dated as of April 26, 2018, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1020.htm) |
| 10.21^‡ | [Amendment No. 2 to Master Services Agreement, dated as of June 6, 2023, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1021.htm) |
| 10.22‡ | [Assignment Agreement by and among Shah Investor LP and the Company, dated as of August 6, 2013.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1022.htm) |
| 10.23‡ | [Advisory Services Agreement, dated as of August 26, 2024, by and between Wise Orient Investments Limited and Semnur Pharmaceuticals, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1023.htm) |
| 10.23.1‡ | [Amendment to Advisory Services Agreement, dated as of July 22, 2025, by and between Wise Orient Investments Limited and Semnur Pharmaceuticals, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525163401/d887184dex10231.htm) |
| 10.24‡ | [Advisory Services Agreement, dated as of August 25, 2024, by and between 450W42ND MIMA, LLC and Semnur Pharmaceuticals, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1024.htm) |
| 10.24.1‡ | [Amendment to Advisory Services Agreement, dated as of July 22, 2025, by and between 450W42ND MIMA, LLC and Semnur Pharmaceuticals, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525163401/d887184dex10241.htm) |
| 10.25#‡ | [Third Amended and Restated Convertible Promissory Note, dated as of January 24, 2025, issued by Denali Capital Acquisition Corp. to Denali Capital Global Investments LLC.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex1025.htm) |
| 10.26‡ | [Form of Transition Services Agreement, by and between Scilex Holding Company and the Company.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525154936/d887184dex1026.htm) |

---

------

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 10.27‡ | [Stock Issuance Agreement, dated as of July 22, 2025, by and between Semnur Pharmaceuticals, Inc. and the party named therein.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525163401/d887184dex1027.htm) |
| 10.28‡ | [Advisory Services Agreement, dated as of June 12, 2025, by and between JW Investment Management Company Limited and Semnur Pharmaceuticals, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525163401/d887184dex1028.htm) |
| 10.29‡ | [Amendment to Advisory Services Agreement, dated as of July 22, 2025, by and between JW Investment Management Company Limited and Semnur Pharmaceuticals, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525163401/d887184dex1029.htm) |
| 16.1 | [Letter Regarding Change in Accountants (incorporated by reference to Exhibit 16.1 to Denali's Current Report on Form 8-K filed with the SEC on July 17, 2024).](http://www.sec.gov/Archives/edgar/data/1913577/000121390024062099/ea020952101ex16-1_denali.htm) |
| 21.1‡ | [List of Subsidiaries of the Registrant.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex211.htm) |
| 23.1‡ | [Consent of Marcum Asia CPAs LLP, independent registered public accounting firm of Denali Capital Acquisition Corp.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525177097/d887184dex231.htm) |
| 23.2‡ | [Consent of Marcum LLP, former independent registered public accounting firm of Denali Capital Acquisition Corp.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525177097/d887184dex232.htm) |
| 23.3‡ | [Consent of Pipara & Co LLP, independent registered public accounting firm of Semnur.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525177097/d887184dex233.htm) |
| 23.4‡ | Consent of Winston & Strawn LLP (included in Exhibit [5.1](http://www.sec.gov/Archives/edgar/data/1584541/000119312525177097/d887184dex51.htm) and [8.1](http://www.sec.gov/Archives/edgar/data/1584541/000119312525177097/d887184dex81.htm)). |
| 24.1 | [Power of Attorney (included on the signature page to this proxy statement/prospectus).](#sigl) |
| 99.1‡ | [Consent of Henry Ji to be named as a director nominee.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex991.htm) |
| 99.2‡ | [Consent of Jaisim Shah to be named as a director nominee.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex992.htm) |
| 99.3‡ | [Consent of Jay Chun to be named as a director nominee.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex993.htm) |
| 99.4‡ | [Consent of Dorman Followwill to be named as a director nominee.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex994.htm) |
| 99.5‡ | [Consent of Alexander Yue Wu to be named as a director nominee.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex995.htm) |
| 99.6‡ | [Form of Preliminary Proxy Card.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525177097/d887184dex996.htm) |
| 99.7‡ | [Fairness Opinion of CB Capital Partners, Inc. in relation to Valuation of Semnur Pharmaceuticals, Inc. by Denali Capital Acquisition Corp., dated August 30, 2024 (included as Annex H to the proxy statement/prospectus contained in this registration statement).](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1584541/000119312525177097/d887184ds4a.htm#toc887184_275a) |
| 99.8‡ | [Consent of CB Capital Partners, Inc.](http://www.sec.gov/Archives/edgar/data/1584541/000119312525087342/d887184dex998.htm) |
| 101.INS | Inline XBRL Instance Document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document. |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| 107 | [Filing Fee Table.](d887184dexfilingfees.htm) |

---

‡ Previously filed.

\* Indicates management contract or compensatory plan or arrangement.

------

# Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

---

| | |
|:---|:---|
| ^ | Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) information that the Registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC.  |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on the 11th day of August, 2025.

---

| | |
|:---|:---|
| **Denali Capital Acquisition Corp.** | **Denali Capital Acquisition Corp.** |
| By: | /s/ Lei Huang |
|  | Name: Lei Huang |
|  | Title: Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Lei Huang | Chief Executive Officer and Director<br>(Principal Executive Officer) | August 11, 2025 |
| Lei Huang | Chief Executive Officer and Director<br>(Principal Executive Officer) | August 11, 2025 |
| \* | Chief Financial Officer<br>(Principal Financial and Accounting Officer) | August 11, 2025 |
| You ("Patrick") Sun | Chief Financial Officer<br>(Principal Financial and Accounting Officer) | August 11, 2025 |
| \* | Director | August 11, 2025 |
| Huifeng Chang | Director | August 11, 2025 |
| \* | Director | August 11, 2025 |
| Jim Mao | Director | August 11, 2025 |
| \* | Director | August 11, 2025 |
| Kevin Vassily | Director | August 11, 2025 |

---

\* Signed by Lei Huang pursuant to the power of attorney signed by each individual and previously filed with this Registration Statement on November 6, 2024

------

Pursuant to the requirements of the Securities Act, the co-registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on the 11th day of August, 2025.

---

| | |
|:---|:---|
| **Semnur Pharmaceuticals, Inc.** | **Semnur Pharmaceuticals, Inc.** |
| By: | /s/ Jaisim Shah |
|  | Name: Jaisim Shah |
|  | Title: Chief Executive Officer and President |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Jaisim Shah<br> Jaisim Shah | Chief Executive Officer and President<br>(Principal Executive Officer) | August 11, 2025 |
| \*<br> Henry Ji, Ph.D. | Treasurer, Secretary and Director | August 11, 2025 |
| \*<br> Stephen Ma | Principal Financial Officer | August 11, 2025 |

---

\* Signed by Jaisim Shah pursuant to the power of attorney signed by each individual and previously filed with this Registration Statement on November 6, 2024

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

#### Exhibit 107

#### Calculation of Filing Fee Tables

#### FORM S-4
(Form Type)

#### DENALI CAPITAL ACQUISITION CORP.
(Exact Name of Registrant as Specified in its Charter)

#### Table 1: Newly Registered Securities

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | Security <br>Type  | Security Class Title | Fee<br>Calculation<br>Rule | Amount to be<br>Registered | Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit | Maximum<br>Aggregate<br>Offering<br>Price | Fee Rate | Amount of<br>Registration<br>Fee |
| &nbsp;&nbsp;&nbsp;Fees to<br>be paid | (1) | Equity | Common Stock, par value $0.0001 per share | 457(f)(1) | 2091617 | $11.21 | $23447026.57 | $0.0001531 | $3589.74 |
| &nbsp;&nbsp;&nbsp;Fees to<br>be paid | (2) | Equity | Common Stock, par value $0.0001 per share | 457(f)(2) | 281100000 | $0.0000333 | $9370.00 | $0.0001531 | $1.44 |
| &nbsp;&nbsp;&nbsp;Fees to<br>be paid | (3) | Other | Warrants to purchase Common Stock | Other | 8235378 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Fees to<br>be paid | (4) | Equity | Common Stock issuable upon exercise of warrants | 457(c)<br> 457(g)<br>457(i) | 8235378 | $11.55 | $95118615.90 | $0.0001531 | $14562.67 |
| &nbsp;&nbsp;&nbsp;Fees to<br>be paid | (5) | Other | Units, consisting of one share of Common Stock, par value $0.0001 per share, and one Warrant to purchase one share of Common Stock | 457(f)(1) | 524622 | $11.53 | $6048891.66 | $0.0001531 | $926.09 |
| &nbsp;&nbsp;&nbsp;Fees to<br>be paid | (6) | Equity | Common Stock, par value $0.0001 per share, underlying the Units | 457(i) | 524622 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Fees to<br>be paid | (7) | Other | Warrants to purchase Common Stock underlying the Units | 457(i)<br> Other | 524622 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Fees to<br>be paid | (8) | Equity | Common Stock issuable upon exercise of Warrants underlying the Units | 457(g)(1) | 524622 | $11.50 | $6033153 | $0.0001531 | $923.68 |
| &nbsp;&nbsp;&nbsp;Fees to <br>be paid | (9) | Equity | Series A Preferred Stock, par value $0.0001 per share | 457(f)(2) | 6000000 | $0.0000333 | $200.00 | $0.0001531 | $0.04 |
|  |  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  |  | $130657257.13 |  | $20003.66 |
|  |  | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid |  |  |  |  |  |
|  |  | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  | $20003.66 |
|  |  | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  |  | $— |

---

------

#### **Table of Contents**
(1) On August 30, 2024, Denali Capital Acquisition Corp., a Cayman Islands exempted company ("Denali"), entered into that certain Agreement and Plan of Merger with Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali ("Merger Sub"), and Semnur Pharmaceuticals, Inc., a Delaware corporation ("Semnur") and a wholly owned subsidiary of Scilex Holding Company ("Scilex") (as amended from time to time in accordance with its terms including by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 16, 2025, the "Merger Agreement"). Pursuant to the Merger Agreement, among other things, (a) Denali will effect a deregistration under the Cayman Islands Companies Act (2023 Revision) (As Revised) and a domestication under Section 388 of the Delaware General Corporation Law, pursuant to which the jurisdiction of incorporation for Denali will be changed from the Cayman Islands to the State of Delaware (the "Domestication"), (b) Merger Sub will merge with and into Semnur, with Semnur surviving such merger (the "Business Combination") as a direct wholly owned subsidiary of Denali (which will be renamed Semnur Pharmaceuticals, Inc. ("New Semnur")). All securities being registered will be issued by New Semnur.

The Merger Agreement provides, among other things, that (i) each outstanding share of common stock of Semnur ("Semnur Common Stock") as of immediately prior to the time at which the Business Combination becomes effective (the "Effective Time") (other than shares held by Semnur or its subsidiaries or shares the holders of which exercise dissenters' rights of appraisal) will be automatically converted into the right to receive a number of newly issued shares of common stock of Denali (following the Domestication), par value $0.0001 per share ("New Semnur Common Stock"), equal to the Exchange Ratio (as defined in the Merger Agreement), (ii) each outstanding share of preferred stock of Semnur ("Semnur Preferred Stock") as of immediately prior to the Effective Time will be automatically converted into the right to receive (a) one share of Series A Preferred Stock of Denali (following the Domestication), par value $0.0001 per share, and (b) one-tenth of one share of New Semnur Common Stock and (iii) subject to the approval of the Option Exchange Proposal described in the proxy statement/prospectus forming part of this registration statement, each option to purchase Semnur Common Stock that is outstanding as of immediately prior to the Effective Time will be exchanged for a number of options exercisable for newly issued shares of New Semnur Common Stock based upon the Exchange Ratio. <br>

The amount to be registered represents shares of New Semnur Common Stock issuable in exchange for all outstanding Denali ordinary shares in connection with the Domestication. Pursuant to Rule 457(f)(1) promulgated under the Securities Act of 1933, as amended (the "Securities Act") and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.21, based on the average of the high ($11.89) and low ($10.52) prices of Denali Class A ordinary shares on the OTC Markets on April 16, 2025 (such date being within five business days of the date that this registration statement was filed with the Securities and Exchange Commission (the "SEC")). No cash is to be received or paid by the Registrant in connection with the securities to be issuable in connection with the Business Combination. <br>

For all securities set forth in this table, the amount to be registered also includes, pursuant to Rule 416(a), an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock splits or similar transactions. <br>

------

(2) The amount to be registered represents: (a) 280,500,000 shares of New Semnur Common Stock, the maximum number of shares of New Semnur Common Stock that are expected to be issued in connection with the Business Combination to (i) holders of Semnur Common Stock and (ii) assuming approval of the Option Exchange Proposal described in the proxy statement/prospectus forming part of this registration statement, holders of outstanding options to purchase shares of Semnur Common Stock, and (b) 600,000 shares of New Semnur Common Stock, the maximum number of shares of New Semnur Common Stock issuable to holders of Semnur Preferred Stock in connection with the Business Combination. The value per share of the securities to be received by the Registrant upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) under the Securities Act. Semnur is a private company, no market exists for its securities, and Semnur has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by the Registrant in connection with the securities to be exchanged in the Business Combination.

(3) The amount to be registered represents the 8,235,378 public warrants of Denali issued and outstanding, which will be exchanged for warrants to purchase New Semnur Common Stock in connection with the Domestication. The maximum number of warrants to purchase New Semnur Common Stock being exchanged for the 8,235,378 public warrants of Denali issued and outstanding and shares of New Semnur Common Stock issuable upon exercise of such warrants are being simultaneously registered hereunder. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations, the registration fee with respect to such warrants has been allocated to the shares of New Semnur Common Stock underlying such warrants and those shares of New Semnur Common Stock are included in the registration fee as calculated in footnote (4) below.

(4) The amount to be registered represents the shares of New Semnur Common Stock issuable upon exercise of warrants to purchase New Semnur Common Stock. Each such warrant will entitle the warrant holder to purchase one share of New Semnur Common Stock at a price of $11.50 per whole share of New Semnur Common Stock (subject to adjustment). Pursuant to Rule 457(g) promulgated under the Securities Act and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.55, based on (a) the exercise price of the $11.50 per whole share of New Semnur Common Stock as described in this footnote (4), plus (b) the average of the high ($0.05) and low ($0.05) prices of the Denali public warrants on The Nasdaq Global Market on October 29, 2024 (such date being within five business days of the date that this registration statement was filed with the SEC).

(5) The amount to be registered represents 14,662 public units issued and outstanding that were sold in the Registrant's initial public offering and 510,000 private placement units issued and outstanding that were sold in a private placement in connection with the initial public offering, which will be exchanged for a corresponding number of units of New Semnur in connection with the Domestication. Each unit may be redeemed for one share of New Semnur Common Stock and one warrant to purchase New Semnur Common Stock. The value per share of the securities to be received by the Registrant upon the issuance of such securities and pursuant to Rule 457(f)(1) promulgated under the Securities Act and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.53, based on the average of the high ($11.53) and low ($11.53) prices of the public units of Denali each consisting of one Class A ordinary share and one redeemable warrant on The Nasdaq Global Market on October 29, 2024 (such date being within five business days of the date that this registration statement was filed with the SEC). No cash is to be received or paid by the Registrant in connection with the securities to be issued in connection with the Business Combination.

(6) Pursuant to Rule 457(i), there is no fee associated with the registration of shares of common stock issuable upon conversion of the units being registered under this Registration Statement because no additional consideration will be received in connection with the conversion of units.

(7) The amount to be registered represents 14,662 public warrants of Denali and 510,000 private warrants of Denali underlying the units referenced in footnote (5) above. The maximum number of warrants to purchase New Semnur Common Stock being exchanged for these warrants and shares of New Semnur Common Stock issuable upon exercise of such warrants are being simultaneously registered hereunder. Consistent with the response to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations, the registration fee with respect to such warrants has been allocated to the shares of New Semnur Common Stock underlying such warrants and those shares of New Semnur Common Stock are included in the registration fee as calculated in footnote (7) below.

------

(8) The amount to be registered represents New Semnur Common Stock issuable upon exercise of warrants to purchase New Semnur Common Stock. Each such warrant will entitle the warrant holder to purchase one share of New Semnur Common Stock at a price of $11.50 per whole share of New Semnur Common Stock (subject to adjustment). Pursuant to Rule 457(g) of the Securities Act and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share of the New Semnur Common Stock underlying the warrants is the exercise price of $11.50 per share.

(9) The amount to be registered represents the maximum number of shares of New Semnur Common Stock issuable to the holders of Semnur Preferred Stock in connection with the Business Combination. The value per share of the securities to be received by the Registrant upon the issuance of such securities and the proposed maximum offering price per share is estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) under the Securities Act. Semnur is a private company, no market exists for its securities, and Semnur has an accumulated deficit. Therefore, the proposed maximum offering price per share is one-third of the aggregate par value of the securities expected to be exchanged in the Business Combination. No cash is to be received or paid by the Registrant in connection with the securities to be issuable in connection with the Business Combination.

Table 2: Fee Offset Claims and Sources

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Registrant or<br>Filer Name | Form<br>or<br>Filing<br>Type | File Number | Initial Filing<br>Date | Filing Date | Fee Offset<br>Claims | Security<br>Type<br>Associated<br>with Fee<br>Offset | Unsold<br>Securities<br>Associated<br>with Fee<br>Offset | Unsold<br>Aggregate<br>Offering<br>Amount<br>Associate | Fee Paid with<br>Fee Offset<br>Source |
| &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) |
| &nbsp;&nbsp;&nbsp;Fee<br>Offset<br>Claims | Denali<br>Capital<br>Acquisition<br>Corp. | Form S-4 | 333-283019 | 11/6/2024 |  | $20003.66 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Fee<br>Offset<br>Sources | Denali<br>Capital<br>Acquisition<br>Corp. | Form S-4 | 333-283019 |  | 11/6/2024 |  |  |  |  | $20003.66 |

---

#### Rule 457(b)
The Registrant previously paid $21,347.37 with the respect to all securities included herein based on a maximum aggregate offering price of $139,433,933.54 in connection with its filing of the Registration Statement on Form S-4 (File No. 333-283019) (of which this exhibit is a part) on November 6, 2024 in connection with the Business Combination. In accordance with Rule 457(b) under the Securities Act, the Registrant is using $20,003.66 of the previously paid fees to offset the filing fee payable in connection with this amendment to this Registration Statement.